Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Transcripts
    • AGM Invitations
    • IPOs
  • inderesTV
  • Forum
  • Discovery
  • About Us
    • Our Coverage
    • Team

Optomed

2.52 EUR

+2.03 %

5,660 following
Corporate customer

OPTOMED

NASDAQ Helsinki

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Dividend
Investor consensus
Compare
+2.03 %
+2.24 %
-34.08 %
-33.29 %
-32.75 %
-28.14 %
-38.36 %
-74.75 %
-45.09 %

Optomed operates in the medical technology sector. The company conducts research and development of specialized eye cameras. Development takes place of both hardware and software that are resold under different brands. Operations are held on a global level, with the largest presence in the Nordic market. Customers consist of research institutes and hospitals. The company has its headquarters in Oulu.

Read more
Market cap
53.96M EUR
Turnover
269.57K EUR
P/E (adj.) (26e)
-15.12
EV/EBIT (adj.) (26e)
-14.72
P/B (26e)
2.64
EV/S (26e)
2.74
Dividend yield-% (26e)
-
Coverage
Recommendation
Buy
Target price
3.80 EUR
Updated
11.02.2026
Disclaimer
Juha Kinnunen
Juha Kinnunen

Analyst

Latest research

Latest analysis report

Released: 11.02.2026

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
6.5
2026

Interim report Q1'26

8.5
2026

General meeting '26

14.8
2026

Interim report Q2'26

Risk
Business risk
Valuation risk
Low
High
All
Research
Webcasts
Press releases
ShowingAll content types
Regulatory press release4/9/2026, 10:00 AM

Optomed Oyj: Notice Of The Annual General Meeting Of Optomed Plc

Optomed
US market roadmap for medical devices – a European perspective
Analyst Comment3/27/2026, 10:45 AM by
Antti Siltanen

US market roadmap for medical devices – a European perspective

Success in the US requires success in several sub-areas.

BioretecAiforia TechnologiesNightingale HealthNexstimOptomedRevenio GroupModulightBiohit
Regulatory press release2/27/2026, 7:00 AM

Optomed Oyj: Disclosure under Chapter 9, Section 10 of the Securities Markets Act regarding change in holdings

Optomed

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release2/25/2026, 7:00 AM

Optomed Oyj: Optomed Annual Report 2025 published

Optomed
Press release2/11/2026, 12:31 PM

Redeye: Optomed Q4 (Review): Devices segment supports outlook despite cautious guidance

Optomed
Optomed Q4'25: Vækstselskaber skal levere vækst
Research2/11/2026, 6:00 AM by
Juha Kinnunen

Optomed Q4'25: Vækstselskaber skal levere vækst

Optomeds vækstforventninger for 2026 var svage, hvilket fik markedet til at skære en fjerdedel af aktiens værdi.

Optomed
Press release2/10/2026, 12:16 PM

Redeye: Optomed Q4 (Initial take): Sales in line; EBIT impacted by a one-off cost

Optomed
Regulatory press release2/10/2026, 7:00 AM

Optomed Oyj: Optomed Plc: Financial Statements Bulletin January - December 2025

Optomed
Optomed Q4'25 preview: Fokus på forventninger
Analyst Comment2/6/2026, 4:06 AM by
Juha Kinnunen

Optomed Q4'25 preview: Fokus på forventninger

Optomed offentliggør sit Q4 regnskab næste tirsdag. Hovedfokus i regnskabet er rettet mod omsætningsvækstprognosen for 2026, som vi forventer vil være i form af "stærk vækst". Vores opmærksomhed i regnskabsmeddelelsen er især rettet mod den kommercielle udvikling af vækstfaktorerne i Udstyr-segmentet, såsom Aurora AEYE-løsningen og Optomed Lumo.

Optomed
Regulatory press release1/29/2026, 11:30 AM

Optomed Oyj: Proposal of Optomed's Nomination Board

Optomed
Optomed modtager internationalt anerkendt cybersikkerhedscertifikat
Analyst Comment1/21/2026, 3:44 PM by
Juha Kinnunen

Optomed modtager internationalt anerkendt cybersikkerhedscertifikat

Optomed
Press release1/21/2026, 9:00 AM

Optomed Oyj: Optomed Achieves ISO 27001 Certification for Information Security Management Systems

Optomed
Press release1/12/2026, 7:00 AM

Optomed Oyj: Optomed and Aireen Announce Strategic Partnership and Achieve Approval for AI-Powered Handheld Diabetic Retinopathy Screening

Optomed
Life Science Companies as Investments | Life Science Night Dec. 9, 202514:40
Video12/16/2025, 7:30 AM

Life Science Companies as Investments | Life Science Night Dec. 9, 2025

Antti Siltanen, Life Science Analyst, PhD, talks about life science companies as investments.

Aiforia TechnologiesBioretecBiohitFaron PharmaceuticalsModulightNexstimOrionBittiumDetection TechnologyOptomedRevenio GroupNightingale HealthHerantis PharmaNanoform Finland
Regulatory press release12/12/2025, 1:45 PM

Optomed Oyj: New shares subscribed for in Optomed Plc's directed share issue have been registered in the Finnish Trade Register

Optomed
Regulatory press release12/10/2025, 8:00 PM

Optomed Oyj: Inside information: Optomed Plc successfully completes directed share issue raising approximately EUR 6.0 million

Optomed
Press release11/7/2025, 7:48 AM

Redeye: Optomed Q3 (Review) - Solid growth with a positive devices segment development

Optomed
Regulatory press release11/6/2025, 7:00 AM

Optomed Oyj: Optomed Plc: Interim Report, January - September 2025

Optomed
Regulatory press release9/26/2025, 1:30 PM

Optomed Oyj: Optomed Plc - Managers' transactions - Myllylä

Optomed
Regulatory press release9/26/2025, 1:30 PM

Optomed Oyj: Optomed Plc - Managers' transactions - Piila

Optomed
Forum discussions
Did the ketchup bottle open: LinkedIn #aiinhealthcare #digitalhealth #medicalai #chinahealthcare #optomed... Thrilled to share that over the past week, I had the privilege to support our JV partner Optomed Plc in taking a solid new step in China’s healthcare market. Through collaboration...
4/17/2026, 4:10 AM
by Mr. Stock
43
Optomed heading to Egypt with Stubb. Presidentti – 17 Apr 26 Presidentti Stubb viralliselle vierailulle Egyptiin - Presidentti Tasavallan presidentin kansliaTiedote 23/202617.4.2026 Tasavallan presidentti Alexander Stubb on virallisella vierailulla Egyptin arabitasavallassa 21.–22...
4/17/2026, 12:34 PM
by Jankkeri
39
No one can certainly accuse this company of over-hyping; I’d perhaps hope for slightly more active investor communication, even just at the press release level. Otherwise, it wouldn’t matter that much, but since capital has been raised through share issues and similar financing risks...
4/17/2026, 5:19 AM
by Markus
27
The game is now open in the massive Chinese market. These customer contracts could start coming in at a steady pace. Wiser Asia is a great partner in this. Based on what I’ve read, health sector operators in China rely heavily on pilots conducted by leading institutions. In other...
yesterday
by j.sälli
24
A few Chinese articles with interesting context. These really convey that China is moving fast + they align with these LinkedIn observations and locations: In December 2025, Guangdong health authorities announced that AI-based diagnostic and screening solutions (including fundus ...
6 hours ago
by Mr. Stock
21
Apparently they are screening for more than just retinopathy… #notbad 眼底一张照 慢病早知道 → “One fundus photo – chronic diseases detected early” 眼底筛查 → “Fundus screening” 广州市荔湾区社区卫生服务中心 → “Guangzhou Liwan District Community Health Service Center”
4/17/2026, 2:04 PM
by Mr. Stock
21
Great catch! China seems to be picking up momentum now. It looks like there will be revenue coming from China as early as Q2, even though Himberg only promised it for H2.
4/17/2026, 4:22 AM
by Sheikki
21
Read more on our forum
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.